Status:
TERMINATED
Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer
Lead Sponsor:
Steba Biotech S.A.
Collaborating Sponsors:
International Drug Development Institute
PrimeVigilance Ltd., UK
Conditions:
Low Risk Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
Multiple center, single-arm, open-label, 12-month follow-up phase IV pragmatic clinical trial in men with unilateral prostate cancer meeting eligibility criteria for the drug (as per the European Econ...
Detailed Description
This is a multiple center, single-arm, open-label, 12-month follow-up phase IV pragmatic clinical trial. Men with unilateral prostate cancer meeting eligibility criteria for the drug (as per the EEA M...
Eligibility Criteria
Inclusion
- Men over 18 years of age with a life expectancy ≥ 10 years
- .Unilateral adenocarcinoma of the prostate accurately located and confirmed as unilateral using high resolution biopsy strategies based on current best practice, such as multi- parametric MRI based strategies or template-based biopsy procedures.
- Clinical stage T1c or T2a,
- Gleason Score ≤ 6, based on high-resolution biopsy strategies
- 3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1 -2 positive cancer cores with ≥ 50 % cancer involvement in any one core or a PSA density ≥ 0.15 ng/mL/cm3.
- PSA ≤ 10 ng/mL
- If the patient is sexually active with women who are capable of getting pregnant, he and/or his partner should use an effective form of birth control to prevent getting pregnant during a period of 90 days after the VTP procedure.
- Signed Informed Consent Form
Exclusion
- GENERAL EXCLUSION CRITERIA :
- Unwillingness to accept the treatment;
- Any previous prostatic interventions where the internal urinary sphincter may have been damaged, including trans-urethral resection of the prostate (TURP) for benign prostatic hypertrophy.
- Participation in another clinical study involving an investigational product within 1 month before study entry;
- Inability to understand the informed consent document, to give consent voluntarily or to complete the study tasks, especially inability to understand and fulfill the health-related QOL questionnaire;
- Subjects in custody and or residing in a nursing home or rehabilitation facility;
- Biopsy proven locally advanced or metastatic prostate cancer.
- SURGERY AND OTHER TREATMENT-RELATED CONDITIONS OF EXCLUSION
- Any condition or history of illness or surgery that in the opinion of the investigator might affect the conduct and results of the study or pose additional risks to the subject or any medical condition that precludes the administration of a general anaesthetic or invasive procedures.
- Hypersensitivity to the active substance or to the excipient (mannitol)
- Current or prior treatment for prostate cancer.
- Patients who have been diagnosed with cholestasis.
- Current exacerbation of rectal inflammatory bowel disease.
- Anticoagulant medicinal products and those that decrease platelet aggregation (e.g. acetylsalicylic acid) should be stopped at least 10 days before the procedure with TOOKAD. Medicinal products that prevent or reduce platelet aggregation should not be started for at least 3 days after the procedure.
Key Trial Info
Start Date :
January 21 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 13 2020
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT03849365
Start Date
January 21 2019
End Date
November 13 2020
Last Update
March 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire (CHU)
Angers, France